TELANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
TELA Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$0.97−0.00 (-0.48%)
Close on Oct 19, 2026
- Market cap
- $55.71M
- P/E (TTM)
- –
- Dividend yield
- –
TELA Bio, Inc. revenue by segment
By business segment
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $15.50M | – | – | – | $17.20M | – | – | – | – | – | – | – | 80.3% | -9.9% |
| Non-US | $3.80M | $3.70M | $3.40M | $3.00M | $3.00M | $2.60M | $2.80M | $2.80M | $2.40M | $2.30M | $1.90M | $1.70M | 19.7% | +26.7% |
From the segment and revenue-disaggregation notes of TELA Bio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.